Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 205

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Combination of CSF N -acetylaspartate and neurofilaments in multiple sclerosis

Teunissen, C. E., Iacobaeus, E., Khademi, M., Brundin, L., Norgren, N., Koel-Simmelink, M.J.A., Schepens, M., Bouwman, F., Twaalfhoven, H. A.M., Blom, H. J., Jakobs, C., Dijkstra, C. D. · 2009 · Neurology

Abstract

OBJECTIVE: Axonal degeneration is the likely cause of disease progression in multiple sclerosis (MS). Our previous results indicated that neuron-specific N-acetylaspartate (NAA) is a candidate CSF biomarker for disease progression in MS. The aim of this study was to explore the potential of NAA as an early biomarker of axonal damage in MS. Next, we wanted to know the additional value of measurement of NAA compared to other candidate markers for axonal damage, such as neurofilament subunits and tau protein. METHODS: Levels of NAA, neurofilament light, neurofilament heavy, and tau were determined in CSF of patients with clinically isolated syndrome (CIS, n = 38), relapsing-remitting MS (RRMS, n = 42), secondary progressive MS (SPMS, n = 28), and primary progressive MS (PPMS, n = 6); patients without neurologic disease (ND, n = 28); noninflammatory neurologic controls (n = 18); and inflammatory neurologic controls (n = 39). RESULTS: CSF NAA levels were decreased in patients with SPMS compared to ND controls, patients with CIS, and patients with RRMS. CSF NAA levels in patients with CIS and RRMS were similar to those in ND subjects. All axonal damage proteins showed specific patterns of changes and relations with disease activity measures. The neurofilament light chain levels were already increased in patients with CIS, especially in patients who converted to MS. The neurofilament heavy chain levels were highest in the patients with SPMS. Tau levels were similar in MS and ND. CONCLUSIONS: CSF N-acetylaspartate (NAA) levels were not different from patients without neurologic disease in early stages of multiple sclerosis, though decreased as the disease progressed. Combining CSF NAA and neurofilament levels yields information on different phases of axonal pathology.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0b013e3181a0fe3f

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 205

Metadata

Authors
Teunissen, C. E., Iacobaeus, E., Khademi, M., Brundin, L., Norgren, N., Koel-Simmelink, M. J. A., Schepens, M., Bouwman, F., Twaalfhoven, H. A. M., Blom, H. J., Jakobs, C., & Dijkstra, C. D.
Venue
Neurology
Published
2009-04-14
Volume
72
Issue
15
Pages
1322-1329
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W1984069677
Cited by
205
References
2
FWCI
7.78
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combination of CSF N -acetylaspartate and neurofilaments in multiple sclerosis. https://app.cochat.ai/papers/10.1212/wnl.0b013e3181a0fe3f
The paper
Teunissen, C. E., Iacobaeus, E., Khademi, M., Brundin, L., Norgren, N., Koel-Simmelink, M. J. A., Schepens, M., Bouwman, F., Twaalfhoven, H. A. M., Blom, H. J., Jakobs, C., & Dijkstra, C. D. (2009). Combination of CSF N -acetylaspartate and neurofilaments in multiple sclerosis. Neurology. https://doi.org/10.1212/wnl.0b013e3181a0fe3f

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.